It was suggested that a combined therapeutic strategy, such as the combination of EGFR and mTOR inhibitors, is a reasonable choice for the treatment of TNBC, and recent experiments on TNBC cells demonstrated significant downregulation of cell cycle regulators after exposure to combined treatment [5], assuming that the combination of the EGFR inhibitor gefitinib and the mTOR inhibitor everolimus may achieve an anti-tumor effect similar to that of a single drug by reducing the drug dose [6]; yet, these are still encouraging laboratory research results. This evidence concerns the gene EGFR and neoplasm.